Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
← catalyst calendarSponsored by Coherus Oncology, Inc. (industry) · CHRS — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
30actual
Sites
37
Countries
Australia, South Korea, Taiwan +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-12 | actual | When the study began enrolling |
| Primary completion | 2025-06-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-08 | actual | The whole study's end, after follow-up |
| First posted | 2022-05-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma
Interventions
- Drug: SRF388
- Drug: Atezolizumab — also filed as Tecentriq
- Drug: Bevacizumab — also filed as Avastin
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNature, frequency, and severity of adverse events (AEs) per NCI CTCAE version 5.0 or higher
measured Up to 2 years
Progression Free Survival (PFS) according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)
measured Up to 2 years
Permalink · CHRS's whole pipeline · Catalyst calendar · Every registered study · What changed